Hasegawa, Takeshi <br/><br/>
Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin.  [electronic resource] 

 -  Kidney international  Feb 2011 
 - 340-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1523-1755 
<br/><br/><label>Standard No.: </label>10.1038/ki.2010.382  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Ambulatory Care--legislation & jurisprudence<br/>Anemia--blood<br/>Biomarkers--blood<br/>Drug Costs<br/>Drug Utilization--legislation & jurisprudence<br/>Erythropoietin--administration & dosage<br/>Female<br/>Health Expenditures--legislation & jurisprudence<br/>Health Policy--economics<br/>Hematinics--administration & dosage<br/>Hemoglobins--metabolism<br/>Humans<br/>Insurance, Health, Reimbursement--legislation & jurisprudence<br/>Iron--administration & dosage<br/>Japan<br/>Kidney Failure, Chronic--blood<br/>Male<br/>Middle Aged<br/>National Health Programs--economics<br/>Outcome and Process Assessment, Health Care--economics<br/>Practice Guidelines as Topic<br/>Practice Patterns, Physicians'--economics<br/>Prospective Studies<br/>Recombinant Proteins<br/>Renal Dialysis--economics<br/>Time Factors<br/>Treatment Outcome